SAN FRANCISCO, CA, UNITED STATES, February 26, 2026 /EINPresswire.com/ — Bright Pattern, a global leader in AI-powered omnichannel contact center software, today ...
The decision is supported by the Phase 3 PROTOSTAR study, where guselkumab demonstrated higher levels of skin clearance vs. placebo at Week 16. 2 Almost one-third of Pso cases begin in childhood, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results